Skip to main content

Table 4 Patient Characteristics by Initial Second-Line Antidiabetic Medication Class

From: Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin

Characteristica

Total

SFU

BI

Otherb

N (%)

N (%)

N (%)

N (%)

Total

84,720 (100)

45,734 (54)

12,165 (14)

26,821 (32)

Sex

 Female

43,236 (51)

22,528 (49)

6,683 (55)

14,025 (52)

 Male

41,484 (49)

23,206 (51)

5,482 (45)

12,796 (48)

Age, years

 65-67

22,425 (26)

11,540 (25)

3,604 (30)

7,281 (27)

 68-70

13,145 (16)

6,864 (15)

1,768 (15)

4,513 (17)

 70-74

24,323 (29)

13,244 (29)

3,219 (26)

7,860 (29)

 75-79

13,990 (17)

7,843 (17)

1,937 (16)

4,210 (16)

 ≥80 years

10,837 (13)

6,243 (14)

1,637 (13)

2,957 (11)

Hemoglobin A1c, %

 <8

14,053 (17)

7,216 (16)

1,081 (9)

5,756 (21)

 8-10

11,912 (14)

6,507 (14)

972 (8)

4,433 (17)

 ≥10

4,079 (5)

2,037 (4)

802 (7)

1,240 (5)

 Unavailablec

54,676 (65)

29,974 (66)

9,310 (77)

15,392 (57)

Mean hemoglobin A1c (±SD), %d

7.95 (1.62)

7.95 (1.57)

8.59 (2.14)

7.79 (1.48)

Diabetes Complications

Severity Indexe score

 0

47,026 (56)

25,946 (57)

6,384 (52)

14,696 (55)

 1

15,783 (19)

8,294 (18)

2,268 (19)

5,221 (19)

 2

10,999 (13)

5,892 (13)

1,615 (13)

3,492 (13)

 ≥3

10,912 (13)

5,602 (12)

1,898 (16)

3,412 (13)

Prescriber Specialty

 Endocrinology

3,652 (4)

1,362 (3)

738 (6)

1,552 (6)

 Family practice

33,681 (40)

18,641 (41)

4,595 (38)

10,445 (39)

 Internal medicine

29,543 (35)

16,467 (36)

3,832 (32)

9,244 (34)

 Nurse/PA

6,889 (8)

3,448 (8)

1,141 (9)

2,300 (9)

 Other/Missing

10,955 (13)

5,816 (13)

1,859 (15)

3,280 (12)

Health Plan Type

 Health maintenance organization

25,499 (30)

13,585 (30)

4,070 (33)

7,844 (29)

 Preferred provider organization

8,232 (10)

4,612 (10)

965 (8)

2,655 (10)

 Other

50,989 (60)

27,537 (60)

7,130 (59)

16,322 (61)

Fill Year

 2013

10,112 (12)

6,033 (13)

1,289 (11)

2,790 (10)

 2014

11,766 (14)

6,585 (14)

1,653 (14)

3,528 (13)

 2015

11,046 (13)

6,038 (13)

1,379 (11)

3,629 (14)

 2016

27,639 (33)

14,907 (33)

4,537 (37)

8,195 (31)

 2017

24,157 (28)

12,171 (27)

3,307 (27)

8,679 (32)

  1. BI: basal insulin, SFU: sulfonylurea
  2. a All participant characteristics were significantly associated with initial second-line antidiabetic medication class with a P-value of <0.001
  3. b The Other category comprises DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors, and thiazolidinediones (TZDs)
  4. c Laboratory values are not routinely available in health plan administrative data sources unless submitted by the laboratory vendor as part of their contract with the health payer. For these data, 35% of submitted laboratory claims nationally included a result. The Unavailable category includes patients without evidence of a test (no claim), as well as those with evidence of a test but no available result
  5. d Mean hemoglobin A1c (± SD) was calculated for all participants with available values
  6. e The Diabetes Complications Severity Index (DCSI) is a validated index composed of micro- and macrovascular complications of diabetes. In this analysis, we modified the DCSI by removing cardiovascular diagnoses that comprise the primary exposure variable. Scores were categorized as 0, 1, 2, and ≥3
Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us